How PCSK9 cholesterol drugs will shift pharma's pricing trends

As the new ultra-potent treatment option winds its way through the review process, payers are starting to address cost.

By Nicole Gray • March 25, 2015

The Biogen ripple effect: Analyst recommends Genworth as proxy buy

According to a Raymond James analyst, if Biogen's Alzheimer's drug is approved, it could reduce claims at Genworth Financial—and increase profits.

By Nicole Gray • March 24, 2015

Explore the Trendline➔

Commercialization

New drugs for obesity are becoming blockbusters, while Trump administration pressure is reshaping pharma marketing strategies ahead of looming patent cliffs.

By BioPharma Dive staff

ICYMI: Why 2015 is the year of the biopharma blockbuster (with charts)

11 new products could reach blockbuster status by 2019, compared to just three products from 2014.

By Sy Mukherjee • March 24, 2015

Paper: SSRIs impact teens' sexual function, too

Although many teen patients who take SSRIs—and their physicians—are reluctant to talk about drug-related sexual side effects, they do exist.

By Nicole Gray • March 24, 2015

Here comes the blockbuster: Novartis' Cosentyx bests Stelara in psoriasis trials

Since the drug's approval in January, Novartis has been racking up positive clinical trial data for Cosentyx, showing superiority to both Amgen's Enbrel and now J&J's Stelara.

By Nicole Gray • March 23, 2015

Judge refuses to block Novartis biosimilar of Amgen drug

Sandoz made history earlier this month when it became the first company to receive an FDA approval for a biosimilar.

By Nicole Gray • March 20, 2015

MSF: Sovaldi profit protection measures squeeze out patients in poor nations

Medecins Sans Frontieres says the company's efforts to prevent cheaper Sovaldi (sofosbuvir) from going to rich patients has inadvertently hurt hepatitis C-infected people in poor countries. 

By Nicole Gray • March 18, 2015

New obesity drugs jockey for market uptake

The brave new world of weight-loss drugs has grown in the last few years. But clinicians and patients are still wary of cardiovascular risk. 

By Nicole Gray • March 18, 2015

How Novo Nordisk plans to keep its eyes on the diabetes prize

Kaare Schultz, widely expected to be Novo's next CEO, says diabetes will most likely account for 80% to 90% of sales in the next 10 years.

By Nicole Gray • March 18, 2015

Study: AZ's Brilinta shows promise, but comes with risks

Some experts believe the benefits of the drug will outweigh the risk of bleeding. 

By Nicole Gray • March 16, 2015

Will Pradaxa reversibility be the final death knell for warfarin?

Since 2010, warfarin has lost 25% market share to the new class of oral anticoagulants. So what's next for warfarin? And what's next for Pradaxa?

By Nicole Gray • March 12, 2015

Apple's new ResearchKit raises hopes, questions for medical studies

Will data received through the platform come from a wide enough pool of participants? 

By Nicole Gray • March 11, 2015

Novartis CEO: Watch out for more cost-cutting on the horizon

Joe Jimenez is continuing to cut costs by trimming the company's back-office staff and consolidating business units.

By Nicole Gray • March 10, 2015

Bangladeshi pharma launches $10 version of Sovaldi

Incepta Pharma's mega-cheap (and unauthorized) version of the $1,000 pill reportedly launched last month.

By Nicole Gray • March 9, 2015

UPDATE: Shire's Boston move involves 'mass layoff' of up to 600 employees

The company is trimming its Chesterbrook, PA workforce by 600, and it's unclear how many of those employees will get to keep their jobs after the move to Boston.

By Nicole Gray • March 6, 2015

AstraZeneca to spin off antibiotics R&D for $40 million

The decision to spin off the Waltham, MA-based antibiotics division will allow AZ to focus on key pipelines.

By Nicole Gray • March 5, 2015

Genentech denies knowledge of distribution-related problems

In response to a provocative survey finding that the company's distribution changes led to delays in cancer patients' treatment.

By Nicole Gray • March 5, 2015

AZ board to CEO Soriot: Want that big bonus? Show us the money

After successfully staving off a Pfizer takeover last year, the AZ CEO promised revenues of $45 billion by 2023. But sales are down, and now Soriot's bonus is at stake.

By Nicole Gray • March 3, 2015

US lawmakers push Amphastar for answers on naloxone prices

Sen. Bernie Sanders (D-VT) and Rep. Elijah Cummings (D-MD) have sent the company a letter to inquire about pricing habits.

By Nicole Gray • March 3, 2015

Survey: New Genentech distribution policy delaying cancer patients' care

The company's new distribution policy relies on specialty distributors instead of wholesalers and has increased the price of Avastin, Rituxan, and Herceptin.

By Nicole Gray • March 3, 2015

A booming Bayer projects 10% pharma-driven growth in 2015

Bayer is projecting a major increase in sales of its top five drugs to roughly $4.6 billion for 2015.

By Nicole Gray • Feb. 27, 2015

GSK's CEO faces another pay cut—and it's a big one

Andrew Witty is facing a net pay cut of 46%.

By Nicole Gray • Feb. 27, 2015

Shire puts binge-eating disorder on the medical map

With celebrity endorsements, advocacy-group buy-in, and aggressive DTP and DTC advertising, Shire is helping patients define a newly recognized disorder.  

By Nicole Gray • Feb. 26, 2015

Federal judge strikes down Maine's controversial prescription drug import law

PhRMA wins the first round of this legal battle. It's unclear if Maine will appeal the ruling.

By Nicole Gray • Feb. 26, 2015

It's been a good year: Juno's top management nabs big bonuses

Juno's CEO Hans Bishop received a $450,000 bonus, while CFO Steve Harr received $200,000.

By Nicole Gray • Feb. 26, 2015